| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/PAS.0B013E3181D96231 |
| P698 | PubMed publication ID | 20421783 |
| P50 | author | Erinn Downs Kelly | Q91879291 |
| Manfred Dietel | Q1889297 | ||
| P2093 | author name string | Lin Wang | |
| Ricardo V Lloyd | |||
| Mark Stoler | |||
| Fabien Gaire | |||
| James Pettay | |||
| Margaret Loftus | |||
| Raymond Tubbs | |||
| Christopher Roberts | |||
| Michael Bilous | |||
| Bettina G Papouchado | |||
| Andre M Oliveira | |||
| Ray Nagle | |||
| Jonathan Myles | |||
| Patrick Roche | |||
| Thomas Grogan | |||
| Adrienne Morey | |||
| William Powell | |||
| Jim Ranger-Moore | |||
| Abigail McElhinny | |||
| Nichole Prescott | |||
| Heather Free | |||
| Carole Ferrell Garcia | |||
| Lidija Dragovich | |||
| P4510 | describes a project that uses | fluorescence in situ hybridization | Q1336182 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast carcinoma | Q18555947 |
| reproducibility | Q1425625 | ||
| P304 | page(s) | 767-776 | |
| P577 | publication date | 2010-06-01 | |
| P1433 | published in | The American Journal of Surgical Pathology | Q7713508 |
| P1476 | title | Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility. | |
| P478 | volume | 34 |
| Q54538229 | Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH). |
| Q38612634 | Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens |
| Q55032245 | Application of the 2013 ASCO/CAP guideline and the SISH technique for HER2 testing of breast cancer selects more patients for anti-HER2 treatment. |
| Q47700657 | Assessment of HER-2 status in invasive breast cancer in Brazil. |
| Q38408138 | Biomedical applications of trastuzumab: as a therapeutic agent and a targeting ligand. |
| Q37889274 | Clinical and health economic outcomes of alternative HER2 test strategies for guiding adjuvant trastuzumab therapy |
| Q34084063 | Concomitant detection of HER2 protein and gene alterations by immunohistochemistry (IHC) and silver enhanced in situ hybridization (SISH) identifies HER2 positive breast cancer with and without gene amplification |
| Q48155048 | Counting invasive breast cancer cells in the HER2 silver in-situ hybridization test: how many cells are enough? |
| Q36245435 | Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach |
| Q40544225 | Distinct expression profile of key molecules in crawling-type early gastric carcinoma |
| Q83403908 | Dual-color silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancer |
| Q51175484 | HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer. |
| Q28078111 | HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists |
| Q38314355 | HER2 assessment by silver in situ hybridization: where are we now? |
| Q26822730 | HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies |
| Q53158559 | HER2 status in operable breast cancers from Vietnamese women: Analysis by immunohistochemistry (IHC) and automated silver enhanced in situ hybridization (SISH). |
| Q38326102 | HER2 testing and its predictive utility in anti-HER2 breast cancer therapy |
| Q35195417 | Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method. |
| Q35034555 | Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches |
| Q38394606 | Instant-quality fluorescence in-situ hybridization as a new tool for HER2 testing in breast cancer: a comparative study |
| Q36089948 | MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome |
| Q47254055 | Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. |
| Q90498824 | Prognostic value of systemic inflammatory markers and development of a nomogram in breast cancer |
| Q33862786 | Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update |
| Q34855870 | SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases |
| Q40748887 | Silver-Enhanced In Situ Hybridization as an Alternative to Fluorescence In Situ Hybridization for Assaying HER2 Amplification in Clinical Breast Cancer |
| Q34424285 | Testing for HER2 in Breast Cancer: A Continuing Evolution |
| Q37932507 | The human epidermal growth factor receptor 2 (HER2). |
| Q36821180 | Thymidylate synthase protein expression by IHC and gene copy number by SISH correlate and show great variability in non-small cell lung cancer |
Search more.